HUYA Bioscience International expanded oncology pipeline includes combination with checkpoint inhibitor for solid tumors

San Diego, CA, USA – June 4, 2018 – HUYA Bioscience International (HUYA), the leader in accelerating global development of China’s pharmaceutical innovations, today announced it is at a key stage in the company’s development of HBI-8000, HUYA’s lead novel epigenetic drug with important immunomodulatory properties. HUYA is conducting a Phase 2 trial of HBI-8000 in the US, investigating efficacy and safety in combination with nivolumab for the treatment of solid tumors.

HUYA Bioscience International Establishes Strategic Partnership with Suzhou BioTOP

San Diego, CA, USA – July 10, 2017 – HUYA Bioscience International, the leader in accelerating global development of China’s pharmaceutical innovations, today announced a strategic collaboration agreement with Suzhou BioTOP Technical Service Co., Ltd. (referred to as BioTOP). The collaboration will focus on promoting the development of biomedical innovations from companies and research organizations in Suzhou BioBay that help to meet the increasing demand to fill global pharmaceutical pipelines.

HUYA Bioscience International and CAS Innovation and Investment Company Establish Strategic Collaboration

San Diego, CA, USA – January 18, 2017HUYA Bioscience International (HUYA), the leader in accelerating the global development of China’s pharmaceutical innovations, announced today a strategic collaboration agreement with the Chinese Academy of Sciences Innovation and Investment Company (referred to as CAS Innovation). The collaboration will focus on developing and commercializing biomedical innovations discovered by leading scientists at CAS to meet the medical needs of patients around the world.

HUYA Bioscience International Sponsors 12th Annual Scrip Awards ‘Best New Drug’ Category

San Diego, CA, USA – December 14, 2016 – For the second straight year, HUYA Bioscience International (HUYA) was a proud sponsor of the Best New Drug category at the Annual Scrip Awards.

HUYA Bioscience International Dr. Mireille Gillings Named Pharma Executive of the Year at the BioPharma Industry Awards 2016

Recognized for Visionary Leadership Within Asia’s Pharmaceutical Industry

San Diego, CA, USA – March 24, 2016HUYA Bioscience International (HUYA) Founder and Executive Chair Mireille Gillings, Ph.D., has been named Pharma Executive of the Year at the BioPharma Industry Awards 2016. Presented in conjunction with the 9th BioPharma Asia Convention 2016.

HUYA Bioscience International Celebrates 10 Years in China

Biopharma Company with Joint HQ in Shanghai & San Diego Commemorates a Decade of Innovation

Shanghai, China – March 22, 2016HUYA Bioscience International (HUYA) celebrated the 10th anniversary of the opening of its first offices in China with a gala dinner at the ‘M on the Bund’ restaurant in Puxi, Shanghai.

HUYA Bioscience International Acquires Exclusive Rights to Immuno-Oncology Products from Fudan University

Inhibitors of indoleamine 2,3-dioxygenase to be Developed for Oncology Therapy

San Diego, CA, USA – March 15, 2016HUYA Bioscience International (HUYA), the leader in accelerating global development of China’s pharmaceutical innovations, today announced it has signed an exclusive license with Fudan University for the ex-China rights to a series of novel immuno-oncology drug candidates discovered by Fudan researchers.

HUYA Bioscience International Grants an Exclusive License for HBI-8000 in Japan and Other Asian Countries to Eisai

Eisai to commercialize HUYA’s Product in Lymphoma and Develop New Indications in Solid Tumors

San Diego, CA, USA – February 1, 2016HUYA Bioscience International (HUYA) President, CEO, Executive Chairman & Founder Dr. Mireille Gillings announced that Eisai Co., Ltd. has acquired from HUYA an exclusive license agreement for HBI-8000 in Japan, South Korea, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Singapore.

沪亚生物国际授予日本卫材HBI-8000在日本及其它亚洲国家的独占许可

卫材将在淋巴瘤领域实现沪亚产品的商业化并在实体瘤领域开发新的适应症

美国加州圣迭戈 – 2016年2月1日  –沪亚生物国际总裁、首席执行官、执行董事长和创始人Mireille Gillings博士宣布,日本卫材株式会社经由协议获得了HBI-8000在日本、韩国、泰国、马来西亚、印尼、菲律宾、越南和新加坡的独占许可。

HUYA Bioscience International Adds to Senior Management Team

Appoints Andy Claude, C.P.A., as Vice President, Finance

San Diego, CA, USA – December 23, 2015HUYA Bioscience International (HUYA) today announced the addition of Andy Claude, C.P.A. as Vice President, Finance. His addition to the senior management team will support the company’s international expansion.